Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
Open Access
- 12 December 2011
- journal article
- clinical trial
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (1) , 82-89
Abstract
This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with 177Lu-cG250. Serial planar scintigrams after injection of 111In-cG250 or 177Lu-cG250 in patients with metastasized renal cell carcinoma were analyzed quantitatively. The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic 111In-cG250 data, were determined. Methods: Twenty patients received a diagnostic tracer activity of 111In-cG250 (185 MBq), followed by radioimmunotherapy with 177Lu-cG250. The administered activity of 177Lu-cG250 was escalated by entering 3 patients at each activity level starting at 1,110 MBq/m2, with increments of 370 MBq/m2. After each diagnostic and therapeutic administration, whole-body scintigraphic images and pharmacokinetic data were acquired. Hematologic toxicity was graded using the Common Toxicity Criteria, version 3.0. Diagnostic 111In-cG250 data were used to simulate 177Lu and 90Y data by correcting for the difference in physical decay. Absorbed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therapeutic 177Lu-cG250, simulated 177Lu-cG250, and simulated 90Y-cG250 data. Results: Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the administered activity (r = 0.85), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated and measured 177Lu-cG250 data. Absorbed doses (whole body and red marrow) based on the simulated 177Lu-cG250 data correlated with the observed platelet toxicity (r = 0.65 and 0.82). The tumor–to–red marrow dose ratio was higher for radioimmunotherapy with 177Lu-cG250 than for radioimmunotherapy with 90Y-cG250, indicating that 177Lu has a wider therapeutic window for radioimmunotherapy with cG250 than 90Y. Conclusion: In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with 177Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow–absorbed dose. Diagnostic 111In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with 177Lu-cG250. These estimations indicate that in these patients, higher radiation doses can be guided to the tumors with 177Lu-cG250 than with 90Y-cG250.Keywords
This publication has 19 references indexed in Scilit:
- Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-TositumomabJournal of Nuclear Medicine, 2010
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side EffectsCurrent Drug Metabolism, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND)European Journal of Nuclear Medicine and Molecular Imaging, 2006
- Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic ResponseClinical Cancer Research, 2005
- Radiation Dosimetry for Radionuclide Therapy in a Nonmyeloablative StrategyCancer Biotherapy and Radiopharmaceuticals, 2002
- Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaCritical Reviews in Oncology/Hematology, 2001
- Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Imaging for improved prediction of myelotoxicity after radioimmunotherapyCancer, 1997
- Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapyNuclear Medicine and Biology, 1989